Potential Big Impact If Firms That Own Pharmacy Benefit Managers Must Break Up

Why It Matters

Separating PBMs from their captive pharmacies would cut a major profit engine, forcing the industry to rethink pricing and could lower drug costs for employers and patients. The change also raises antitrust stakes, signaling a broader regulatory push against vertical consolidation in healthcare.

Key Takeaways

• Patients Before Monopolies Act forces PBM owners to sell retail pharmacies.
• Cigna, CVS Health, UnitedHealth would have one year to divest.
• Specialty pharmacy revenue could drop, hitting PBM profit margins.
• Current PBM reforms focus on rebate transparency, not ownership structure.
• Break‑up could reshape drug pricing dynamics across the U.S. market.

Pulse Analysis

The "Patients Before Monopolies Act" marks a decisive shift from incremental PBM transparency measures toward structural antitrust action. By mandating the sale of retail and specialty pharmacies owned by integrated insurers, Congress aims to dismantle the lucrative captive‑pharmacy model that has become a cornerstone of PBM profitability. Specialty pharmacies, which dispense high‑cost biologics and oncology drugs, now account for over a third of PBM earnings, far surpassing the declining rebate share that once dominated the business.

Existing reforms—such as the Consolidated Appropriations Act’s rebate‑pass‑through rules and the FTC’s spread‑pricing ban—target pricing opacity but leave the underlying ownership structure untouched. Those measures improve visibility for employers and plan sponsors but do not address the incentive for PBMs to steer patients toward their own dispensing channels. The new legislation would force the major players—Cigna’s Express Scripts, CVS Health’s Caremark, UnitedHealth’s OptumRx—to separate from their pharmacy networks, potentially unlocking competition among independent pharmacies and reducing the margin padding built into specialty drug distribution.

If the break‑up proceeds, the industry could see a realignment of revenue streams, with PBMs shifting further toward administrative fees and data services while specialty pharmacy profits migrate to independent operators. This transition may accelerate net‑pricing contracts and drive greater price competition for high‑cost therapies, ultimately benefiting employers and patients. Stakeholders should monitor the bill’s progress, as its passage would represent the most consequential regulatory intervention in the U.S. prescription‑drug market in years.